Under one in 10 individuals that would benefit from obesity jabs such as Wegovy can access them, warns the World Health Organization as it issues its first guidance on the medications.
Considering over a billion individuals worldwide now classified as obese, it is advocating for more widespread and fairer availability to this class of drugs.
Per projections, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention.
"The latest guidance acknowledges that obesity is a lifelong illness that can be managed with thorough and ongoing treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and supply-chain constraints are key hurdles to widespread availability to the injections that can help people shift substantial body mass, says the organization.
Skinny Jab Scarcity
Even in the current most optimistic scenario, the manufacturing of such drugs might only reach about 100 million people – under 10% of eligible patients, as stated by the WHO.
The advice urges governments and firms to widen access, via strategies like licensing agreements.
A patent on a key compound – the main component of Novo Nordisk's Wegovy – is due to expire in several countries in 2026.
How Weight-Loss Jabs Work
GLP-1 drugs mimick a biological compound to delay gastric emptying, suppress the appetite and enhance the sense of being full so people reduce food intake.
Individuals typically begin shedding pounds in the initial weeks of commencing the regular doses.
Evidence points to patients may see weight return after a year of discontinuing the drug, because their normal appetite return.
Being carrying excess weight elevates your likelihood for developing medical conditions, including diabetes, heart disease, stroke, and specific malignancies.
Excess weight concerns individuals in all nations and was responsible for 3.7 million deaths worldwide in 2024, according to the health agency.
